Arbor Research Collaborative for Health, Ann Arbor, MI, USA.
University of Michigan, Ann Arbor, MI, USA.
Am J Transplant. 2018 Aug;18(8):1914-1923. doi: 10.1111/ajt.14694. Epub 2018 Mar 24.
Kidney transplant outcomes that vary by program or geopolitical unit may result from variability in practice patterns or health care delivery systems. In this collaborative study, we compared kidney graft outcomes among 4 countries (United States, United Kingdom, Australia, and New Zealand) on 3 continents. We analyzed transplant and follow-up registry data from 1988-2014 for 379 257 recipients of first kidney-only transplants using Cox regression. Compared to the United States, 1-year adjusted graft failure risk was significantly higher in the United Kingdom (hazard ratio [HR] 1.22, 95% confidence interval [CI] 1.18-1.26, P < .001) and New Zealand (hazard ratio [HR] 1.29, 95% confidence interval [CI] 1.14-1.46, P < .001), but lower in Australia (HR 0.90, 95% CI 0.84-0.96, P = .001). In contrast, long-term adjusted graft failure risk (conditional on 1-year function) was significantly higher in the United States compared to Australia, New Zealand, and the United Kingdom (HR 0.74, 0.75, and 0.74, respectively; each P < .001). Thus long-term kidney graft outcomes are approximately 25% worse in the United States than in 3 other countries with well-developed kidney transplant systems. Case mix differences and residual confounding from unmeasured factors were found to be unlikely explanations. These findings suggest that identification of potentially modifiable country-specific differences in care delivery and/or practice patterns should be sought.
肾移植结果因项目或地缘政治单位而异,可能源于实践模式或医疗保健提供系统的差异。在这项合作研究中,我们比较了来自三个大洲的四个国家(美国、英国、澳大利亚和新西兰)的肾移植结果。我们使用 Cox 回归分析了 1988 年至 2014 年期间 379257 名首次单肾移植受者的移植和随访登记数据。与美国相比,英国(危险比 [HR] 1.22,95%置信区间 [CI] 1.18-1.26,P<0.001)和新西兰(HR 1.29,95%CI 1.14-1.46,P<0.001)的 1 年调整后移植物失败风险显著更高,但澳大利亚(HR 0.90,95%CI 0.84-0.96,P=0.001)的风险较低。相比之下,与澳大利亚、新西兰和英国相比,美国的长期调整后移植物失败风险(1 年功能条件下)显著更高(HR 分别为 0.74、0.75 和 0.74,均 P<0.001)。因此,与 3 个具有发达肾移植系统的其他国家相比,美国的长期肾移植结果约差 25%。发现病例组合差异和未测量因素引起的残余混杂不太可能是解释。这些发现表明,应寻求确定潜在的可改变的特定国家的护理提供和/或实践模式差异。